Results 71 to 80 of about 29,210 (297)

A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia

Case Reports in Oncological Medicine, 2016
Introduction. Ibrutinib is commonly used for the treatment of patients with CLL in either first-line or relapsed/refractory settings. Case Presentation.
William Paul Skelton IV, Neeka N. Akhavan, Zachary A. Taylor, Thu-Cuc Nguyen, Hassan Hassan, Tabitha N. Townsend, Prajwol Pathak, Gaurav Trikha, Nam H. Dang, Long H. Dang, Azka Ali   +10 more
doaj   +1 more source

A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy

Medical Mycology Case Reports, 2020
Ibrutinib has revolutionized the treatment of chronic lymphoid malignancies. Despite its success, ibrutinib has been linked with several reports of invasive fungal infections.
Emily M. Eichenberger, Jennifer Saullo, Danielle Brander, Shih-Hsiu Wang, John R. Perfect, Julia A. Messina   +5 more
doaj   +1 more source

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in ...
A. Younes, L. Sehn, P. Johnson, P. Zinzani, X. Hong, Jun Zhu, C. Patti, D. Belada, O. Samoilova, C. Suh, S. Leppä, S. Rai, M. Turgut, W. Jurczak, Matthew Cheung, R. Gurion, S. Yeh, A. López‐Hernandez, U. Dührsen, C. Thieblemont, C. Chiattone, S. Balasubramanian, J. Carey, Grace Liu, S. Shreeve, Steven Sun, S. Zhuang, J. Vermeulen, L. Staudt, W. Wilson   +29 more
semanticscholar   +1 more source

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK

eJHaem, 2021
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017, represented a
Peter Hillmen, Jing Xie, Alan S. M. Yong, Catherine Waweru, Thuy Anh Sorof, Ravi K. Goyal, Keith L. Davis   +6 more
doaj   +1 more source

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

Medicina, 2023
Background and Objectives: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies.
Ana-Maria Moldovianu, Razvan Stoia, Mariana Vasilica, Iulia Ursuleac, Sorina Nicoleta Badelita, Andra Alina Tomescu, Oana Diana Preda, Alexandru Bardas, Mihaela Cirstea, Daniel Coriu   +9 more
doaj   +1 more source

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Journal of Clinical Oncology, 2021
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia ...
W. Wierda, J. Allan, T. Siddiqi, T. Kipps, Stephen Samuel Opat, A. Tedeschi, X. Badoux, B. Kuss, S. Jackson, C. Moreno, R. Jacobs, J. Pagel, I. Flinn, Y. Pak, Cathy Zhou, E. Szafer-Glusman, J. Ninomoto, J. Dean, D. James, P. Ghia, C. Tam   +20 more
semanticscholar   +1 more source

Ibrutinib:
From Molecule to Medicine

International Journal of Hematology and Oncology, 2014
Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agent modulating BCR, which serves as a covalent irreversible inhibitor of BTK. Ibrutinib significantly alters the composition of the tumor microenvironment in CLL, affecting soluble as well as cellular molecular elements without myelosupression. Ibrutinib is
Demirkan, Fatih, Ayyildiz, Orhan, Unal, Ali, KAYNAR, Leylagül, Vural, Filiz, Turgut, Mehmet, ŞAHİN, FAHRİ, SAYINALP, NİLGÜN, SAYDAM, GÜRAY, Ozdemir, Evren, Ilhan, Osman, Haznedaroglu, Ibrahim C., GÖKER, HAKAN   +12 more
openaire   +4 more sources

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Second-generation inhibitors of Bruton tyrosine kinase

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
doaj   +1 more source

Emerging 2D Materials and Their Hybrid Nanostructures for Label‐Free Optical Biosensing: Recent Progress and Outlook

Advanced Functional Materials, EarlyView.
This review highlights recent advances in label‐free optical biosensors based on 2D materials and rationally designed mixed‐dimensional nanohybrids, emphasizing their synergistic effects and novel functionalities. It also discusses multifunctional sensing platforms and the integration of machine learning for intelligent data analysis.
Xinyi Li, Yonghao Fu, Yuehe Lin, Dan Du
wiley   +1 more source